🇺🇸 FDA
Pipeline program

Upadacitinib (ABT-494)

M14-533

Phase 3 small_molecule active

Quick answer

Upadacitinib (ABT-494) for Ulcerative Colitis (UC) is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie
Indication
Ulcerative Colitis (UC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials